‘Real world’ UK information shows 70% decline in COVID infections after first

England’s coronavirus vaccine project is significantly reducing cases of COVID-19, with a drop of around 70% in infections among health care employees who have had a first dosage of the Pfizer-BioNTech shot, British health officials said on Monday.

Data evaluated by Public Health England (PHE) showed the Pfizer provided high levels of defense against infection and symptomatic disease from a single dose, and that hospitalisation and death from COVID-19 will be minimized by more 75% in senior individuals who have had a first dosage.

“In general, we’re seeing a really strong impact to lowering any infection, asymptomatic and symptomatic,” PHE’s strategic reaction director Susan Hopkins told a media briefing.PHE’s head of immunisation Mary Ramsay described the data as “strong evidence that the Pfizer-BioNTech vaccine is stopping people from getting infected, while also safeguarding cases against hospitalisation and death”.”We should be really encouraged by these preliminary findings,” she said.PHE’s findings originated from two separate analyses – one is an ongoing study in healthcare employees, and the second is an evaluation of screening information in people aged 80 and over.Evidence from the elderly group showed that a person dose of the Pfizer shot is 57% effective versus symptomatic COVID-19 disease, PHE stated, and early data suggest the 2nd dosage enhances security to more than 85%.”Hospitalisation and deaths rates are falling in all age groups, however the oldest age groups are seeing the fastest declinesince the peak in mid-January,” a PHE declaration said. The vaccine also supplies defense against the so-called British version of the SARS-CoV-2 coronavirus, it added.The PHE information come as preliminary study findings from Scotland on Monday also showed the vaccination drive there is working, noticeably reducing the risk of hospitalisation for COVID-19. Scottish scientists said those findings suggested that both the Pfizer and the Oxford-AstraZeneca COVID-19 vaccines are highly reliable in avoiding extreme infections.

Please follow and like us:

Check Also

United States FDA approves Johnson & Johnson’s single dosage COVID 19 vaccine

“Initial results from a large trial in the United States, Latin America and South Africa …

RSS
LinkedIn
Share